Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kintor Pharmaceutical Limited has successfully enrolled the first participant in its pivotal clinical trial for KX-826 tincture, aimed at treating male androgenetic alopecia in China. This step marks significant progress in a study designed to assess the efficacy and safety of their innovative treatment. Additionally, their long-term safety trial has shown promising results, indicating excellent safety and tolerability of the drug.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.